Celldex Therapeutics, Inc. (FRA:TCE2)
Germany
· Delayed Price · Currency is EUR 23.60
+1.00 (4.42%)
At close: Dec 4, 2025
Celldex Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -224.53 | -157.86 | -141.43 | -112.33 | -70.51 | -59.78 | Upgrade
|
| Depreciation & Amortization | 3.38 | 3.18 | 3.01 | 2.9 | 3.07 | 3.93 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.02 | 0.02 | - | 0 | -0.02 | -0.06 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 3.5 | 18 | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.34 | -15.75 | -6.22 | 0.84 | -3.21 | -0.73 | Upgrade
|
| Stock-Based Compensation | 37.09 | 34.24 | 23.89 | 15.61 | 8.95 | 3.92 | Upgrade
|
| Other Operating Activities | - | - | - | -6.86 | -1.63 | -5.39 | Upgrade
|
| Change in Accounts Receivable | 0.76 | 1.93 | -2.28 | -0.18 | 1.57 | -0.79 | Upgrade
|
| Change in Accounts Payable | 14.42 | 11.63 | 9.38 | 3.12 | 3.65 | 1.64 | Upgrade
|
| Change in Other Net Operating Assets | -2.29 | -35.16 | 6.36 | -6.85 | -6.28 | -1.15 | Upgrade
|
| Operating Cash Flow | -179.48 | -157.78 | -107.29 | -103.73 | -60.91 | -40.4 | Upgrade
|
| Capital Expenditures | -2.19 | -1.92 | -1.82 | -1.83 | -1.25 | -1.55 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.07 | 0.03 | 0.06 | Upgrade
|
| Investment in Securities | 179.88 | -288.21 | -103.96 | 91.7 | -214.93 | -96.72 | Upgrade
|
| Investing Cash Flow | 177.69 | -290.13 | -105.78 | 89.94 | -216.16 | -98.22 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 2.96 | Upgrade
|
| Total Debt Issued | - | - | - | - | - | 2.96 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -2.96 | Upgrade
|
| Total Debt Repaid | - | - | - | - | - | -2.96 | Upgrade
|
| Issuance of Common Stock | 1.43 | 441.45 | 218.46 | 4.08 | 272.37 | 171.23 | Upgrade
|
| Financing Cash Flow | 1.43 | 441.45 | 218.46 | 4.08 | 272.37 | 171.23 | Upgrade
|
| Net Cash Flow | -0.36 | -6.46 | 5.39 | -9.71 | -4.69 | 32.6 | Upgrade
|
| Free Cash Flow | -181.67 | -159.7 | -109.11 | -105.56 | -62.16 | -41.96 | Upgrade
|
| Free Cash Flow Margin | -6990.00% | -2274.89% | -1585.19% | -4478.57% | -1336.44% | -565.60% | Upgrade
|
| Free Cash Flow Per Share | -2.74 | -2.48 | -2.25 | -2.25 | -1.45 | -1.42 | Upgrade
|
| Levered Free Cash Flow | -105.94 | -91.67 | -46.7 | -58.03 | -29.71 | -22.62 | Upgrade
|
| Unlevered Free Cash Flow | -105.94 | -91.67 | -46.7 | -58.03 | -29.71 | -22.62 | Upgrade
|
| Change in Working Capital | 12.9 | -21.6 | 13.46 | -3.9 | -1.05 | -0.3 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.